Kexon Pharmaceuticals announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received a marketing license for injectable paclitaxel approved and issued by the British Medicines and Health Products Administration. The commercial name of this drug is Apexelsin, and it is indicated for the treatment of various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer. The albumin paclitaxel dosage form has clinical advantages, improved safety and patient compliance, high clinical approval, and indispensable clinical value in the field of tumor treatment.

Kexon Pharmaceuticals announced that its partner Zhejiang Haichang Biomedical Technology Co., Ltd. recently received a marketing license for injectable paclitaxel approved and issued by the British Medicines and Health Products Administration. The commercial name of this drug is Apexelsin, and it is indicated for the treatment of various cancers such as metastatic breast cancer, metastatic pancreatic cancer, and non-small cell lung cancer. The albumin paclitaxel dosage form has clinical advantages, improved safety and patient compliance, high clinical approval, and indispensable clinical value in the field of tumor treatment.